In the late autumn of 2024, the lab’s electronic screen glowed with a striking time: 21:17.
The deadline set by the CDE for supplementary data on API and formulation loomed like a sword overhead. Only 30 days remained to complete the submission.
Outside the glass curtain wall, phoenix tree leaves rustled in the wind; inside, 31 ultra-performance liquid chromatograph (UPLC) systems hummed relentlessly.
Mr. Wen, the analytical department manager, recalled recurring feedback from previous projects: further characterize the impurity profiles of process-related and degradation impurities. Staring intently at the chromatograms on his computer screen, he frowned deeply.
“We cannot let any impurity go undetected. Patient safety comes first. There must still be room for improvement… How should we proceed?” His question plunged the lab into sudden silence, broken only by the sharp tapping of knuckles against the whiteboard.
“We can design a stepwise validation strategy.” Manager Wen stood up abruptly, explaining his idea while sketching on the whiteboard. “We can apply liquid chromatography–mass spectrometry (LC‑MS) technology… confirm the specificity between degradation impurities and the main peak… fully validate the specificity of testing methods, optimize quality control to the highest standard, and leave no impurity undetected!”
“This round of supplementary review also sets higher requirements for developers. It involves not only the development of conventional HPLC, GC and physicochemical analyses, but also method development for advanced instruments such as LC-MS and GC-MS.” Manager Feng recalled that throughout the month, the team proactively broke disciplinary boundaries, continuously exchanged knowledge, worked day and night, and even took turns staying on duty during holidays.
Especially during the critical supplementary submission period, testing workload surged overwhelmingly. The analytical team responded rapidly: the synthesis staff ran an average of 18 experiments daily, while each analyst operated two to three instruments per day.
On November 17, 2024, the project team completed all supplementary research and documentation sorting within 38 working days. They clarified degradation pathways, rationalized impurity attribution, and ensured method specificity and controllability, successfully addressing all CDE requests.
This leap from chromatographic peaks to mass spectra not only secured quality control for the new drug’s market approval and ensured medication safety but also marked a solid step forward in the team’s journey toward innovative drug quality research.